Quantum Biopharma Ltd.
corporate_fare Company Profile
Quantum Biopharma Ltd. (NASDAQ:QNTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for QNTM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for QNTM spans 6-K.
Recent high-impact activity:
- Quantum BioPharma Posts $17.3M Nine-Month Loss; Cash Rises to $3.56M on ATM and Debenture Funding
- Quantum BioPharma Insiders Lift Voting Control to 68% Via C$80.86 MVS Placement; Reverse-Split Authority Approved
- Quantum BioPharma's Market Manipulation Lawsuit Consolidated; Grant & Eisenhofer Named Lead Counsel
- Quantum BioPharma Taps Thermo Fisher's PPD to Run Phase 2 Lucid-MS Trial
- Quantum BioPharma Moves to Voluntarily Delist from Canadian Securities Exchange
Short Interest & Short Volume
4.52 days to coverFINRA reported short interest of 440,005 shares in QNTM as of the October 30, 2026 settlement, a 15.4% decrease from the prior period — about 4.5 days to cover at its recent average daily volume. On November 20, 2026, 35.1% of QNTM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
QNTM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.